BELLUS Health Inc. (BLU)
| Market Cap | 215.04M |
| Revenue (ttm) | 8,871 |
| Net Income (ttm) | -30.14M |
| Shares Out | 78.34M |
| EPS (ttm) | -0.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $2.86 |
| Previous Close | $2.73 |
| Change ($) | 0.13 |
| Change (%) | 4.76% |
| Day's Open | 2.91 |
| Day's Range | 2.82 - 3.01 |
| Day's Volume | 1,469,753 |
| 52-Week Range | 2.01 - 4.96 |
AJRD, BLU, GMBL, LITE, and PSXP have been added to the Zacks Rank #5 (Strong Sell) List on May 25, 2021
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
AFYA, BLU, CHRA, DHX, and EBMT have been added to the Zacks Rank #5 (Strong Sell) List on May 18, 2021
Los Angeles, California--(Newsfile Corp. - May 17, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BELLUS Health Inc. ("BE...
New York, New York--(Newsfile Corp. - May 17, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September 5...
New York, New York--(Newsfile Corp. - May 16, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of BELLU...
TORONTO--(BUSINESS WIRE)--Morganti & Co., A pro-investor law firm with licensed and experienced lawyers in Canada and the United States that represent investors announces the filing of a securities clas...
New York, New York--(Newsfile Corp. - May 14, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased BELLUS Health Inc. ("...
New York, New York--(Newsfile Corp. - May 14, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BELLUS Health Inc. (NASDAQ: BLU) alleging tha...
New York, New York--(Newsfile Corp. - May 14, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September 5...
Los Angeles, California--(Newsfile Corp. - May 14, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BELLUS Health Inc. ("BE...
New York, New York--(Newsfile Corp. - May 14, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of BELLU...
LOS ANGELES--(BUSINESS WIRE)---- $BLU #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BELLUS Health Inc. (BLU)
Los Angeles, California--(Newsfile Corp. - May 13, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BELLUS Health Inc. ("BE...
NEW YORK, May 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BELLUS Health Inc. ("BELLUS" or the "Company") (NASDAQ: BLU). Such investors are advised to contact...
NEW YORK, May 12, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action...
Los Angeles, California--(Newsfile Corp. - May 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BELLUS Health Inc. ("BE...
New York, New York--(Newsfile Corp. - May 12, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BELLUS Health Inc. ("BELLUS" or "the Compan...
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Bellus (BLU) delivered earnings and revenue surprises of -33.33% and -60.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
NEW YORK, May 5, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September 5, 2019 and July ...
New York, New York--(Newsfile Corp. - April 30, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BELLUS Health Inc. ("BELLUS" or "the Comp...
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BELLUS Health Inc. ("BELLUS" or "the Company") (...
New York, New York--(Newsfile Corp. - April 27, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September...
New York, New York--(Newsfile Corp. - April 23, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September...
NEW YORK, April 19, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class acti...
NEW YORK, April 16, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September 5, 2019 and Ju...
LOS ANGELES, April 16, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BELLUS Health Inc. ("BELLUS" or "the...
New York, New York--(Newsfile Corp. - April 13, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BELLUS Health Inc. (NASDAQ: BLU) alleging t...
LOS ANGELES, April 13, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired B...
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
LOS ANGELES, April 12, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming May 17, 2021 deadline to file a lead plaintiff motion in the class action filed on beha...
Los Angeles, California--(Newsfile Corp. - April 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BELLUS Health Inc. ("B...
NEW YORK, April 6, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BELLUS Health Inc. ("BELLUS" or the "Company") (NASDAQ: BLU). Such investors are advised to contac...
LOS ANGELES, April 2, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BELLUS Health Inc. ("BELLUS" or "the ...
BENSALEM, Pa., April 2, 2021 /PRNewswire/ -- Law Offices of Howard G.
NEW YORK, April 2, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class actio...
New York, New York--(Newsfile Corp. - April 1, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September ...
NEW YORK, March 31, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September 5, 2019 and Ju...
SAN DIEGO & LAVAL, Quebec--(BUSINESS WIRE)---- $BLU #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of BELLUS Health Inc. (NASDAQ: BLU) filed a class action complaint ag...
Los Angeles, California--(Newsfile Corp. - March 30, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BELLUS Health Inc. ("...
SAN DIEGO--(BUSINESS WIRE)-- #BELLUScase--The suit alleges defendants issued false statements concerning BELLUS business and prospects, resulting in its stock trading at inflated prices.
New York, New York--(Newsfile Corp. - March 24, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BELLUS Health Inc. (NASDAQ: BLU) alleging t...
LOS ANGELES--(BUSINESS WIRE)---- $BLU #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 17, 2021 deadline to file a lead plaintiff motion in the class action filed ...
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
New York, New York--(Newsfile Corp. - March 23, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of BELLUS Health Inc. .Shareholders...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September 5, 2019 and July 5, 2020, in...
New York, New York--(Newsfile Corp. - March 23, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased BELLUS Health Inc. ...
About BLU
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. The company was founded in 1993 and is headquartered in Laval, Canada.
| Industry Biotechnology | Founded 1993 |
| CEO Roberto Bellini | Employees 32 |
| Stock Exchange NASDAQ | Ticker Symbol BLU |
Financial Performance
In 2020, BELLUS Health's revenue was 15,000, a decrease of -44.44% compared to the previous year's 27,000. Losses were -31.76 million, 22.1% more than in 2019.